利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

54 条记录 (耗时 0.049 秒)

    POTENT, STABLE AND NON-IMMUNOSUPPRESSIVE ANTI-CD4 ANTIBODIES
    11.
    发明申请
    POTENT, STABLE AND NON-IMMUNOSUPPRESSIVE ANTI-CD4 ANTIBODIES 审中-公开
    POTENT，稳定和非免疫性抗CD4抗体

    公开(公告)号：US20130195881A1

    公开(公告)日：2013-08-01

    申请号：US12597841

    申请日：2008-04-28

    申请人： Sanjaya Singh ,  Sek Chung Fung ,  Dan Huang

    发明人： Sanjaya Singh ,  Sek Chung Fung ,  Dan Huang

    IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

    CPC分类号： C07K16/2812 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/77

    摘要： Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies are also disclosed that have amino acid substitutions that reduce binding to Fc receptor and ADCC activity that also result in a surprising effect on CD4 internalization. In addition, genes for such antibodies are disclosed that have been modified such that they have increased expression over their unmodified counterparts.

    摘要翻译： 公开了特异性结合CD4的新型抗体及其片段。 公开了抗-CD4抗体在铰链区具有氨基酸取代，其可防止链内二硫键形成，从而导致抗体分子具有惊人改善的二价稳定性。 增加的稳定性便于制造并提供增加的体内稳定性。 还公开了具有降低与Fc受体和ADCC活性的结合的氨基酸取代的抗体，其也导致对CD4内在化的惊人效应。 此外，公开了已经修饰的这些抗体的基因，使得它们在未修饰的对应物上具有增加的表达。

    NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF
    13.
    发明申请
    NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF 有权
    新型抗IL13​​抗体及其用途

    公开(公告)号：US20120214971A1

    公开(公告)日：2012-08-23

    申请号：US13308186

    申请日：2011-11-30

    申请人： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    发明人： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    IPC分类号： C07K16/24 ,  C07K16/46

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

    摘要翻译： 本发明涉及对糖基化和非糖基化的人IL13具有特异性和高亲和力结合的抗IL13​​抗体，不结合小鼠IL13，并以约2摩尔比（MAb：IL13）中和人IL13活性 ）。 本发明还涉及这些抗体在治疗IL13介导的疾病中的用途，所述疾病包括过敏性疾病，如过敏性疾病，包括哮喘，过敏性哮喘，非过敏性（内源性）哮喘，过敏性鼻炎，特应性皮炎，过敏性结膜炎，湿疹，荨麻疹 ，食物过敏，慢性阻塞性肺疾病，溃疡性结肠炎，RSV感染，葡萄膜炎，硬皮病和骨质疏松症。

    Anti-IL13 antibodies and uses thereof
    20.
    发明授权
    Anti-IL13 antibodies and uses thereof 有权
    抗IL13​​抗体及其用途

    公开(公告)号：US08734797B2

    公开(公告)日：2014-05-27

    申请号：US13275658

    申请日：2011-10-18

    申请人： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    发明人： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    IPC分类号： A61K39/00

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

    摘要翻译： 本发明涉及对糖基化和非糖基化的人IL13具有特异性和高亲和力结合的抗IL13​​抗体，不结合小鼠IL13，并以约2摩尔比（MAb：IL13）中和人IL13活性 ）。 本发明还涉及这些抗体在治疗IL13介导的疾病中的用途，所述疾病包括过敏性疾病，如过敏性疾病，包括哮喘，过敏性哮喘，非过敏性（内源性）哮喘，过敏性鼻炎，特应性皮炎，过敏性结膜炎，湿疹，荨麻疹 ，食物过敏，慢性阻塞性肺疾病，溃疡性结肠炎，RSV感染，葡萄膜炎，硬皮病和骨质疏松症。